

GENENT.046DV1



6/B
H. 5.10.02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Caras et al. #5
Appl. No. : 10/021,121
Filed : December 6, 2001
For : AL-2 NEUROTROPHIC
FACTOR
Examiner : Unknown

) Group Art Unit 1645

) I hereby certify that this correspondence and
) all marked attachments are being deposited
) with the United States Postal Service as first-
) class mail in an envelope addressed to:
) United States Patent and Trademark Office,
) PO Box 2327, Arlington VA 22202, on

) March 27, 2002

) (Date)

) 
) Ginger R. Dreger, Reg. No. 33,055

SECOND PRELIMINARY AMENDMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

The present Secondary Preliminary Amendment is submitted for entry in regards to the above-mentioned application, and is necessitated by the submission of formal drawings in response to a Notice to File Corrected Application Papers mailed on February 6, 2002.

Kindly amend this application in the following aspects.

In the Specification:

Please replace the paragraph, beginning at page 5, line 33, with the following rewritten paragraph:

B1
--Figure 1A-1C shows the AL-21-encoding nucleotide sequence (SEQ ID NO: 1), its complementary sequence, and the deduced amino acid sequence of AL-2 of the isolated AL-21 ("AL-2-long") cDNA (SEQ ID NO: 2). The deduced N-terminus of the mature AL-2 protein begins with glycine-27 as numbered from the initiation methionine. The C-terminal hydrophobic